Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of Krazati® (Adagrasib) in Combination With Cetuximab for Adult Patients With Previously Treated Kras G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (Crc)
愛文思控股宣佈Krazati® (Adagrasib)與Cetuximab聯合用於已治療過的Kras G12C突變局部晚期或轉移性結直腸癌 (Crc)的成年患者獲得美國FDA加速批准